In Re Trasylol Settlement
Bayer resolved certain claims for $60 Million for patients who suffered failure and death as a result of the drug Trasylol.
Trasylol was a drug used to prevent excessive bleeding during heart surgery. The science unequivocally showed Trasylol can cause kidney damage, heart failure and strokes, and greatly increase patients’ risk of post-surgery death when compared to rival treatments. In 2006, a study by Dr. Dennis Mangano was published in the New England Journal of Medicine concluding that the drug more than doubled the risk of renal failur.After fourteen years on the market, Bayer suspended sales in November 2007. The Lyon Firm participated in this settlement.